Cargando…

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing

Cisplatin (CDDP) is a drug for high-grade osteosarcoma (HGOS) treatment. Several germline pharmacogenetic studies have revealed associations between single nucleotide polymorphisms (SNPs) and CDDP-based therapy response or CDDP-related toxicity in patients with HGOS. Whether these variants could pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattinger, Claudia Maria, Casotti, Chiara, Patrizio, Maria Pia, Luppi, Silvia, Fantoni, Leonardo, Scotlandi, Katia, Ibrahim, Toni, Serra, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570120/ https://www.ncbi.nlm.nih.gov/pubmed/36233089 http://dx.doi.org/10.3390/ijms231911787

Ejemplares similares

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
por: Hattinger, Claudia Maria, et al.
Publicado: (2020)

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
por: Hattinger, Claudia Maria, et al.
Publicado: (2023)

Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
por: Hattinger, Claudia Maria, et al.
Publicado: (2021)

Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
por: Serra, Massimo, et al.
Publicado: (2021)

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments
por: Fanelli, Marilù, et al.
Publicado: (2020)

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
por: Scotlandi, Katia, et al.
Publicado: (2020)

ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma
por: Belisario, Dimas Carolina, et al.
Publicado: (2020)

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
por: Hattinger, Claudia M., et al.
Publicado: (2016)

Pharmacogenomics: What is Next?
por: di Iulio, Julia, et al.
Publicado: (2012)

MiRNAs in Canine and Human Osteosarcoma: A Highlight Review on Comparative Biomolecular Aspects
por: Leonardi, Leonardo, et al.
Publicado: (2021)

Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells
por: Vella, Serena, et al.
Publicado: (2016)

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy
por: Pasello, Michela, et al.
Publicado: (2011)

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma
por: Godel, Martina, et al.
Publicado: (2020)

miR-486-5p expression is regulated by DNA methylation in osteosarcoma
por: Namløs, Heidi M., et al.
Publicado: (2022)

Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice
por: Marques da Costa, Maria Eugenia, et al.
Publicado: (2018)

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
por: Rose, Maimon C., et al.
Publicado: (2014)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing
por: Wadelius, Mia, et al.
Publicado: (2011)

Deciphering next-generation pharmacogenomics: an information technology perspective
por: Potamias, George, et al.
Publicado: (2014)

Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow
por: Giannopoulou, Efstathia, et al.
Publicado: (2019)

Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines
por: Garofalo, Cecilia, et al.
Publicado: (2015)

CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression
por: Martinelli, Marcella, et al.
Publicado: (2016)

Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
por: Racanelli, Dominga, et al.
Publicado: (2020)

Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
por: Racanelli, Dominga, et al.
Publicado: (2020)

A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response
por: Pellegrini, Evelin, et al.
Publicado: (2022)

Pharmacogenomics in Children: Advantages and Challenges of Next Generation Sequencing Applications
por: Vanakker, O. M., et al.
Publicado: (2013)

Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy
por: Zhang, Xindi, et al.
Publicado: (2022)

Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells
por: Evangelisti, Camilla, et al.
Publicado: (2020)

Multimodal evaluation of osteosarcoma choroidal metastasis
por: Fernández Mancebo, Federico M., et al.
Publicado: (2022)

Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts
por: Just, Katja S., et al.
Publicado: (2019)

Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice
por: Tafazoli, Alireza, et al.
Publicado: (2021)

Analysis of population-specific pharmacogenomic variants using next-generation sequencing data
por: Ahn, Eunyong, et al.
Publicado: (2017)

Population Pharmacogenomics for Health Equity
por: Jordan, I. King, et al.
Publicado: (2023)

Pharmacogenomics
Publicado: (2008)

Pharmacogenomics
Publicado: (2008)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma
por: Li, Cuiyun, et al.
Publicado: (2018)

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin
por: Liu, Qing, et al.
Publicado: (2020)

Identification of genes contributing to cisplatin resistance in osteosarcoma cells
por: Xie, Mingzhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4und8fbdv3sivf9afcqgo9vo7l